ATIAP | ADVANCED THERAPEUTICS INDUSTRY ACCELERATION PARTNERSHIP

From Canadian Discovery to Canadian Prosperity

The Advanced Therapeutics Industrial Acceleration Partnership (ATIAP)

THE ASK: *$75 million over four years to build a national pipeline-to-production platform that de-risks Canadian innovations, attracts and anchors private investment in Canada and helps research and companies translate and scale.*

CANADA HAS THE SCIENCE. THE CHALLENGE IS CAPTURING THE VALUE.

Canada has world-class science and has made significant public investments in research and biomanufacturing. At a time of heightened trade uncertainty and global competition for investment, the challenge is ensuring those investments translate into companies, capital, manufacturing and growth anchored in Canada. The missing link is translating, financing, manufacturing and scaling more discoveries in Canada.

THE GAP

- Private capital usually enters only after technical, clinical and manufacturing risk has been reduced, meaning jurisdictions that provide this early de-risking are better positioned to attract subsequent investment and development activity.
- Early CMC, CTA-enabling work, clinical validation and GMP readiness are under-supported.
- Result: Canadian IP, jobs, manufacturing activity, private investment and future value can migrate as assets mature.

ATIAP: A NATIONAL PIPELINE-TO-PRODUCTION PLATFORM

ATIAP is a proposed four-year, $75M national partnership of Stem Cell Network, CASTL, Capital BioVentures and OBIO® that bridges publicly funded discovery to the clinical, manufacturing, commercial and workforce milestones required for investment and scale. ATIAP is implementation-ready, leveraging proven and trusted organizations, expertise and infrastructure.

WHAT ATIAP DOES

- **De-risks** technologies through translational and early clinical work.
- **Optimizes** CMC, process and GMP readiness for Canadian manufacturing.
- **Prepares** companies to attract growth capital, scale in Canada, commercialize and achieve health-system adoption.
- **Builds** the workforce required to scale advanced therapeutics in Canada.

The Economic Imperative

Canada has invested heavily in world-class research, skilled talent and biomanufacturing infrastructure. In an environment of heightened trade uncertainty and intensifying global competition for strategic investment, the next challenge is turning those assets into a reason for capital to choose Canada. ATIAP would help Canadian discoveries become investable sooner, connect them with domestic manufacturing capacity, and create stronger companies around which additional private

investment can accumulate. Without that bridge, follow-on capital, intellectual property, manufacturing activity, jobs and future tax revenues risk being captured by competing jurisdictions. **ATIAP is designed to intervene before value leaves Canada.**

21 Canadian life-sciences companies valued above $500M acquired by foreign entities over the past 15 years	**76%** of investors in later-stage Canadian life-sciences financings above $50M are international	**$75M** proposed four-year federal investment to build the missing bridge from discovery to investment and production

How ATIAP works: integrated, stage-gated support across the commercialization pathway

The four partners bring complementary capabilities that are currently fragmented into one stage-gated pipeline so promising technologies can move through the clinical, manufacturing, commercial and workforce milestones required to become globally competitive, investment-ready industrial assets anchored in Canada.

Program area	Investment	Primary output
Translational / CTA-enabling	**$16.5M**	~22 projects
Early-stage clinical trials	**$12M**	~12 trials
CMC + manufacturing readiness	**$16.5M**	~26-28 projects
Commercialization + venture readiness	**$13M**	~20-22 companies
Talent + workforce development	**$8M**	~800 trained; ~650 workforce-ready
Coordination + governance	**$9M**	National delivery, data, accountability

Stem Cell Network	CASTL	Capital BioVentures	OBIO®
Translational & clinical de-risking	Workforce & technical readiness	Manufacturing & business readiness	Capital access & commercialization

The $75M/4-year investment proposal

Four-year KPI package

22 CTA-enabling studies	**12** early-stage clinical trials	**26-28** CMC / manufacturing-readiness projects	**12-14** investment-ready companies

Additional targets: 12-14 clinical-grade products or products ready for manufacture; ~800 people trained; ~650 workforce-ready participants; 70% post-program employment target (~455 employment outcomes); and increased use of Canadian biomanufacturing infrastructure.

ATIAP | ADVANCED THERAPEUTICS INDUSTRY ACCELERATION PARTNERSHIP

The 10-year Economic Dividend: Capture Greater Value In Canada

ATIAP is not a discovery research program. Rather it is an economic conversion platform that spans the full pipeline from academic translational projects, early clinical trials, CMC/manufacturing-readiness to support of early-stage Canadian companies. Its economic value comes from keeping more development, investment, employment and manufacturing activity in Canada as projects mature.

1 Anchor Canadian development activity	2 Attract and anchor private capital in Canada	3 Build industry-ready talent
$120-660M Illustrative 10-year company-development spending in Canada. A partial proxy only: ATIAP also creates activity through academic projects, clinical trials and manufacturing-readiness work.	**$30-336M foreign + $15-100M domestic** Illustrative capital attracted as Canadian assets are de-risked toward clinical, manufacturing and investment milestones, with the objective of keeping resulting activity in Canada.	**~650 workforce-ready; ~455 targeted employment outcomes** Based on a 70% post-program employment target. If sustained over 10 years, ~455 outcomes could represent ~$364M in employment income and ~$114-119M in payroll-related contributions.

Note: The 10-year figures above are illustrative indicators of the economic footprint ATIAP could enable, not forecasts. The spending and capital ranges reflect low-, medium- and high-growth scenarios. Where a dollar scenario is modelled using supported companies, it should be read as a partial proxy: it does not capture all the economic activity generated by academic projects, clinical trials, manufacturing-readiness or workforce development.

Pre-commercial development is economic activity. Before a therapy reaches market, academic projects and companies allocate significant resources on R&D, clinical trials, CMC/process development, CROs, laboratories, manufacturing, quality systems and specialized regulatory/IP services. Where that work occurs determines which economy captures the jobs, spending, infrastructure use and capability. Once that is established, it is difficult to move jurisdictions. This makes early-stage development a strategic investment-attraction opportunity: jurisdictions that can provide the infrastructure, talent and de-risking support needed at this stage are better positioned to attract follow-on capital and establish long-term industrial activity.

An example of this is Turnstone Biologics, a clinical-stage company focused on developing therapies for solid tumors. Over a five-year period, the company raised approximately $180M that was invested into the Canadian economy through R&D, salaries, manufacturing, contracting support and clinical trials activity.

ATIAP will provide the conditions necessary for companies to create pre-commercial economic activity, anchor within Canadian borders and attract investment at a higher valuation.

Why The Intervention Matters Now

- **Economic:** Build more investment-ready Canadian companies, attract and anchor domestic and international capital, keep IP and development at home, and increase the return on public investment in research and manufacturing.
- **Health:** Advance Canadian-led clinical activity, translate advanced therapeutic innovations and provide increased access and hope for patients.
- **Security:** Strengthen domestic biologics and advanced-therapy capability, build dual-use readiness, reduce exposure to trade and supply-chain disruption, strengthen resilience and reduce dependence on foreign supply chains.

A Canadian proof point: targeted de-risking can unlock much larger pools of capital

SCN provided $500,000 for a critical de-risking step for Vancouver-based Aspect Biosystems. The resulting data package later contributed to a global diabetes partnership worth up to US$2.6B; the next phase is expected to maintain 117 jobs, create 283 jobs and support 268 co-op placements in Canada. ATIAP would replicate this investment-leveraging model across a national pipeline of Canadian advanced-therapeutics opportunities.

The Federal Decision

ATIAP is seeking a four-year, $75 million Budget 2026 investment to establish an integrated national platform that de-risks Canadian discoveries, prepares advanced therapeutics and companies for clinical development and manufacturing, builds industry-ready talent, and creates a stronger pipeline of Canadian opportunities capable of attracting domestic and international investment. By making those assets investable earlier and connecting them to Canadian infrastructure, ATIAP increases the likelihood that capital is deployed, companies scale, and intellectual property and manufacturing activity remain in Canada as their value grows.

The immediate objective is to secure federal support for ATIAP through the Budget 2026 process and a clear pathway for advancing the proposal across government.

ATIAP turns Canada's scientific advantage into a durable Canadian economic advantage.